Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
about
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsSmall-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of LiteratureRole of microRNAs in chemoresistancePersonalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practiceHistopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumorsPatients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case reportMolecular chess? Hallmarks of anti-cancer drug resistanceIncidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study.Tumor necrosis targeted radiotherapy of non-small cell lung cancer using radioiodinated protohypericin in a mouse model.New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer.Drug Resistance to EGFR Inhibitors in Lung CancerThe mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patientsTransformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases.FAIM2, as a novel diagnostic maker and a potential therapeutic target for small-cell lung cancer and atypical carcinoid.Genetic alterations and protein expression in combined small cell lung cancers and small cell lung cancers arising from lung adenocarcinomas after therapy with tyrosine kinase inhibitors.Concomitant T790M mutation and small-cell lung cancer transformation after acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor.YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor CellsRepurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-κB/GLUT1 axis.Small cell lung cancer transformation during immunotherapy with nivolumab: A case report.microRNAs: An Emerging Paradigm in Lung Cancer Chemoresistance.Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.Overexpression of BRCA1 attenuates the sensitivity of PC9 cells to gefitinib.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological diseaseEmerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.The pharmacogenomics of drug resistance to protein kinase inhibitors.Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.Ablating all three retinoblastoma family members in mouse lung leads to neuroendocrine tumor formation.Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets.Biopsy and re-biopsy in lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspirationEpithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis.What's New in SCLC? A Review.Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report.Secondary biopsy of non-oncogenic-driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases.Mutation of the TERT promoter leads to poor prognosis of patients with non-small cell lung cancer.CCR7 promote lymph node metastasis via regulating VEGF-C/D-R3 pathway in lung adenocarcinoma.Adenocarcinoma of the Lung Acquiring Resistance to Afatinib by Transformation to Small Cell Carcinoma: A Case Report.Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.
P2860
Q26741318-A449B9BC-D4B5-463B-9A6F-43D81CECF616Q26766283-EC4098A7-961A-463F-AB1C-8C41922E3834Q26770485-A7AFE2C7-D790-4812-8715-DB946DDFCCE8Q28071903-249F72A9-4F64-48A3-84E2-15CCD54B38C0Q28077504-8E5589D4-0800-4FF5-9AB9-980957BEBCFFQ33879174-356B8B9D-8AEC-4B69-B7EE-BDE346F30ABDQ36240941-1BC0BE0A-E1DD-4E33-A995-236F74A3233EQ36406111-2C5972EE-52D4-4BD6-9F16-CF29FC8D1203Q36413470-FD7340E8-4E50-4499-A342-1D1E89BD0DA1Q36750591-D7D163B3-8969-4384-96F8-8AE96691DAF0Q36834883-6E74CE55-C49A-4BA0-BF66-BD6165EBFC47Q37022191-256C4715-60DE-4AE6-B9CD-F1BCB15357D3Q37133262-4299791A-DF76-402A-9AAE-44936CB7A3A9Q37291399-E3945B4E-0FE7-4619-A14E-E4C212CB7076Q37376246-C9F41C20-1C3F-4677-B54F-753B92A13BD1Q37515387-B3BCA27C-2C31-46D2-BEB8-46898AABE2B6Q37544346-9501502D-EFA6-41D9-A5BF-25C33F0F1564Q37565357-5FBA56A6-09E8-4155-870D-70D31A710747Q37611641-92FA79D0-9C27-44A3-BD85-5BA9A95D8240Q37699414-F4B4D46B-86FD-4D4A-9280-2115A638AF90Q37733355-4B71ABE8-984E-4FA5-AD1D-CD4A69729BB1Q38638204-B1F8EA17-98ED-4205-9BB4-416F760413F0Q38685481-6A672E31-F38B-4450-A2F5-D659B246A7B1Q38731759-C5C2A769-6B18-4E9A-98FD-170AD97A551CQ38807186-08F1B556-DC23-487D-93D8-F08132EB90B1Q38831232-A34D22E0-2B6E-4D40-9FB1-19E58324CE7BQ38930155-6F14E25A-BA7E-4172-92FA-01C9EB446DD6Q38952751-4DFB4435-C602-48A0-BB94-74C1D95C9B1EQ39002233-1090E4FB-DCB8-4684-AB2A-803EA4B76F9FQ39102749-122F358D-1F9F-416B-B3D1-2C5353C6923FQ39172297-8075F0E9-6511-4E90-83FE-A2088B10B9BFQ39365868-7219959D-EDC6-4933-9707-A8B6069A11BAQ39415339-A06C4CB0-A780-416D-AB66-E4FE4FB47AD8Q40049841-23E60327-7786-4BE9-B4B9-62784BDD0B92Q40979412-EA037108-E3AA-4303-9CCB-D48D77902468Q40980773-F76CB9AE-F665-4AB9-A0CE-38A6D3A463BDQ41143039-AD3674DE-A6D9-4A21-B211-76D3D0B327C7Q41439903-8073ECC0-303E-4502-AAFA-3BA25538920EQ41601469-BEEC8304-D8AC-48E0-BD66-CFE481B99EF1Q42330188-58226ACF-5CD0-4C04-A3BD-B06CDF1A3822
P2860
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Transformation from non-small- ...... ar drivers and cells of origin
@ast
Transformation from non-small- ...... ar drivers and cells of origin
@en
Transformation from non-small- ...... ar drivers and cells of origin
@nl
type
label
Transformation from non-small- ...... ar drivers and cells of origin
@ast
Transformation from non-small- ...... ar drivers and cells of origin
@en
Transformation from non-small- ...... ar drivers and cells of origin
@nl
prefLabel
Transformation from non-small- ...... ar drivers and cells of origin
@ast
Transformation from non-small- ...... ar drivers and cells of origin
@en
Transformation from non-small- ...... ar drivers and cells of origin
@nl
P2093
P2860
P3181
P1433
P1476
Transformation from non-small- ...... ar drivers and cells of origin
@en
P2093
Jeffrey A Engelman
Lecia V Sequist
Matthew G Oser
Matthew J Niederst
P2860
P304
P3181
P356
10.1016/S1470-2045(14)71180-5
P407
P577
2015-04-01T00:00:00Z